COMP <GO>
TMO vs BRK-A // REVENUE GROWTH (YOY)
Thermo Fisher Scientific Inc (NYSE) VS. Berkshire Hathaway Inc. (NYSE) • 15-METRIC TALLY: TMO 7
— BRK-A 7
▲ REVENUE GROWTH (YOY) LEADER: TMO
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
revenue-growth
3.90%
LAST: $815,600.00 (-0.23%) • MKT CAP: $1.20T
revenue-growth
-1.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMO VS. BRK-A)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMO | BRK-A | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.30% | 8.30% | +1.00 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 30.4x | 12.7x | +17.70 | BRK-A | /valuation <GO> |
| Free Cash Flow Yield | 2.40% | 2.08% | +0.32 | TMO | /fcf-yield <GO> |
| Operating Margin | 17.40% | 33.00% | -15.60 | BRK-A | /operating-margins <GO> |
| Net Profit Margin | 15.10% | 27.10% | -12.00 | BRK-A | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 3.90% | -1.00% | +4.90 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.24% | 0.00% | +0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.50 | 3.02 | +1.48 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.30% | -0.60 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.1 | 67.2 | -8.02 | BRK-A | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 1.13 | -0.19 | BRK-A | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.3x | 16.7x | +19.60 | BRK-A | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $262.22B | $1.20T | -$940.22B | BRK-A | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMO REV | BRK-A REV | TMO GROSS % | BRK-A GROSS % | TMO FCF | BRK-A FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.56B | $247.24B | 44.0% | 44.0% | $6.29B | $25.04B |
| FY 2024 | $42.88B | $249.71B | 44.0% | 44.0% | $7.27B | $11.62B |
| FY 2023 | $42.86B | $254.91B | 44.0% | 44.0% | $6.48B | $37.73B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMO // BETA 0.94
BRK-A // BETA 1.13